GENFIT: May 24, 2023 Combined Shareholders Meeting results
24 Mai 2023 - 7:00PM
-
Quorum of
29.54% on first
convening; allowing
approval of all the
resolutions recommended by the
Board of Directors
Lille (France); Cambridge
(Massachusetts, United States); Zurich (Switzerland);
May 24, 2023 -
GENFIT (Nasdaq and Euronext: GNFT), a late-stage
biopharmaceutical company dedicated to improving the lives of
patients with rare and severe liver diseases, today announced the
results of the Combined Shareholders Meeting which took place on
May 24, 2023. The quorum on first convening amounted to 29.54% and
shareholders approved all of the resolutions, with the exception of
resolution n°26 which was rejected in accordance with the
recommendations of the Board of Directors.
The voting results, resolution by resolution,
are available in the Investors & Media section of the Company’s
website
(https://ir.genfit.com/financial-information/shareholders-meeting).
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical company
dedicated to improving the lives of patients with rare and severe
liver diseases characterized by high unmet medical needs. GENFIT is
a pioneer in liver disease research and development with a rich
history and strong scientific heritage spanning more than two
decades. Thanks to its expertise in bringing early-stage assets
with high potential to late development and pre-commercialization
stages, today GENFIT boasts a growing and diversified pipeline of
innovative therapeutic and diagnostic solutions.
Its R&D pipeline covers six therapeutic
areas via six programs which explore the potential of
differentiated mechanisms of action, across a variety of
development stages (pre-clinical, Phase 1, Phase 2, Phase 3). These
diseases are acute on-chronic liver failure (ACLF), hepatic
encephalopathy (HE), cholangiocarcinoma (CCA), urea cycle disorder
(UCD), organic acidemias (OA) and primary biliary cholangitis
(PBC). Beyond therapeutics, GENFIT’s pipeline also includes a
diagnostic franchise focused on NASH and ACLF.
GENFIT has facilities in Lille and Paris
(France), Zurich (Switzerland) and Cambridge, MA (USA). GENFIT is a
publicly traded company listed on the Nasdaq Global Select Market
and on compartment B of Euronext’s regulated market in Paris
(Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT’s
largest shareholders and holds 8% of the company’s share capital.
www.genfit.com
CONTACT
GENFIT | Investors
Tel: +33 3 2016 4000 | investors@genfit.com
PRESS RELATIONS | Media
Stephanie Boyer – Press relations | Tel: +333
2016 4000 | stephanie.boyer@genfit.com
GENFIT | 885 Avenue Eugène Avinée, 59120 Loos -
FRANCE | +333 2016 4000 |
www.genfit.com
- GENFIT: May 24, 2023 Combined Shareholders Meeting results
Genfit (EU:GNFT)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Genfit (EU:GNFT)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024